Find insight on Samsung Biologics, China biotech companies and more in the latest Market Talks covering Health Care.

Samsung Biologics announced on Thursday that it will create a new holding company, Samsung Epis Holdings, through a simple division. This is to separate the CDMO business from the biosimilar and ...

- Marking the first phase of the company's second Bio Campus, Plant 5 is expected to have shortest construction timeline - Samsung Biologics will maintain the world's largest biomanufacturing ...

Samsung BioLogics, which is 47.8%-owned by Samsung Electronics Co., the South Korean conglomerate’s crown jewel, said Tuesday in a regulatory filing that it would sell 16.5 million shares priced ...

Samsung Biologics, Celltrion lead Korean pharma sector with salaries over 100 million won. Samsung and Celltrion dominate the Korean pharmaceutical industry with record-breaking employee earnings ...

INCHEON, South Korea, Nov. 18, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) officially began construction of its Plant 4 in Incheon, South Korea. Dubbed the "Super Plant," the new ...

Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic ...

Samsung Biologics switched its valuation of its stake in Samsung Bioepis in 2015, which suddenly made it profitable for the first time in 2015 before its listing in a Seoul stock market a year later.

Samsung Biologics (KRX: 207940.KS), a global contract manufacturing and development organization (CDMO), today announced that it has received 'Leadership' status and an A- rating for water ...

Shares of Samsung Biologics Co. and its largest holder Samsung C&T Corp. were volatile after the Korean contract drug manufacturer announced a spin-off plan.. Investors saw the plan — which will ...

SEOUL, South Korea (AP) — A South Korean regulator said Wednesday Samsung Biologics Co. breached accounting rules in a preliminary finding that could deal a big blow to the company and other ...

Samsung BioLogics, the contract drug manufacturing unit of Samsung Group, is planning to raise as much as $2.5 billion from an initial public offering that would value it at roughly $10 billion.